Septerna Inc. (SEPN)
Septerna Inc. (SEPN) Stock Price, Analysis & Data
| Bid | 28.35 |
| Market Cap | 2.28B |
| Revenue (ttm) | 98.88M |
| Net Income (ttm) | -24.24M |
| Beta | n/a |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | n/a |
| Forward PE | -18.4 |
| P/B (ttm) | 5.81 |
| P/S (ttm) | 23.10 |
| Earnings Date | Nov 9, 2026 |
| Ask | 49.92 |
| Volume | 630,314 |
| Avg. Volume (20D) | 415,145 |
| Open | 47.76 |
| Previous Close | 47.76 |
| Day's Range | 47.76 - 51.09 |
| 52-Week Range | 10.74 - 51.09 |
| Analyst | Strong Buy |
| Price Target | 43 (-12.12%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spo...
Financial Performance
In 2025, Septerna's revenue was 45.95M, an increase of 4,174.51% compared to the previous year's 1.07M. Earnings were -48.88M, a decrease of -31.92%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for SEPN stock is "Strong Buy". The 12-month stock price forecast is 43, which is downside of 12.12% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
